First experience of durable cytoreduction in chronic lymphoid leukemia with 177Lu-DOTATATE.

Savovic T; Prior JO; Nicod-Lalonde M; Bressoud A; Roux S; Schaefer N; Meyer M

doi:10.1007/s12032-019-1266-0

Back

Journal article

First experience of durable cytoreduction in chronic lymphoid leukemia with 177Lu-DOTATATE.

Savovic T Nuclear Medicine Department and Molecular Imaging, CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
Prior JO Nuclear Medicine Department and Molecular Imaging, CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
Nicod-Lalonde M Nuclear Medicine Department and Molecular Imaging, CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
Bressoud A Medical Oncology, Clinique Bois-Cerf, Lausanne, Switzerland.
Roux S Interal Medicine, Centre Médical du Bouveret, Bouveret, Switzerland.
Schaefer N Nuclear Medicine Department and Molecular Imaging, CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland. niklaus.schaefer@chuv.ch.
Meyer M Nuclear Medicine Department and Molecular Imaging, CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland.

2019-03-29

Published in:

Medical oncology (Northwood, London, England). - 2019

Cytoreduction Surgical Procedures

Dose-Response Relationship, Drug

Leukemia, Lymphocytic, Chronic, B-Cell

English This is the first described case of effective and durable cytoreduction after PRRT with 177Lu-DOTATATE in a 75-year-old female, with B cell chronic lymphoid leukemia, and well-differentiated metastatic neuroendocrine tumor.

Language